Slowing down the progression of Parkinson’s disease is key to improving outcomes. In this interview with touchNEUROLOGY, Prof. Angelo Antonini (IRCCS San Camillo, Venice, and University of Padova, Italy) presents the core concept of the Movement Disorders Society Task Force on the biological definition of Parkinson’s disease and treatment objectives, and shares his thoughts on the new disease-modifying therapies that target defined molecular mechanisms in Parkinson’s disease that are about to enter clinical trials.
Questions:
- What are the core concepts of the Movement Disorders Society Task Force on the biological definition of Parkinson’s disease, and what are the treatment objectives? (00:13)
- Several disease-modifying therapies that target defined molecular mechanisms in Parkinson’s disease are about to enter clinical trials; what do you hope to see emerge from these studies? (02:54)
The abstract titled ‘Update on disease-modifying treatments’ (Abstract #SYMP01-4) was presented at the European Academy of Neurology Congress 2022, 25–28 June 2022.
Disclosures: Angelo Antonini has served as a consultant for: AbbVie, UCB, Britannia; participated in advisory boards for Jazz Pharmaceutical, Bial; and received honoraria from Bial and Zambon
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of EAN 2022.
